Neurodegenerative Disease | Novartis

Media Release
Sep 26, 2023
Sandoz receives European Commission approval for Tyruko® (natalizumab), first and only biosimilar for multiple sclerosis in Europe
Story
Oct 13, 2022
In neuroscience, “an inflection point in knowledge and technology”
Media Release
Jun 27, 2022
New Novartis extension phase data show nearly 80% of RMS patients treated with Kesimpta® (ofatumumab) had no evidence of disease activity (NEDA-3)
Media Release
Apr 05, 2022
Novartis presents new four-year data on efficacy and safety of Kesimpta® (ofatumumab) in people living with relapsing multiple sclerosis
Media Release
Mar 18, 2022
New peer-reviewed research shows no increased risk of serious COVID-19 infections in Kesimpta® (ofatumumab)-treated adults with multiple sclerosis
Media Release
Mar 08, 2022
Novartis, Voyager Therapeutics reach license option agreement for next-generation gene therapy vectors for neurological diseases
Media Release
Jan 04, 2022
Novartis announces U.S. Court of Appeals for the Federal Circuit (CAFC) upholds validity of Gilenya® (fingolimod) dosage regimen patent
Media Release
Oct 14, 2021
Kesimpta® (ofatumumab) data at ECTRIMS highlights preservation of IgG levels and safety experience over extended exposure (~3.5 years) in people living with relapsing multiple sclerosis
Story
Aug 07, 2019
Using Super-Resolution Microscopy To See Neurodegeneration
Story
Jul 10, 2014
Longevity with vitality: Japanese elders provide examples for healthy aging
Story
Oct 27, 2013
Tackling a rare disease: Working toward a treatment for SMA
Story
Aug 21, 2018
Neuroscientists target Alzheimer’s “silent stage”